Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Sells $10,800.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $18.00, for a total value of $10,800.00. Following the completion of the sale, the insider now owns 189,452 shares in the company, valued at $3,410,136. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, July 15th, Natarajan Sethuraman sold 638 shares of Entrada Therapeutics stock. The shares were sold at an average price of $18.00, for a total value of $11,484.00.
• On Monday, May 20th, Natarajan Sethuraman sold 9,675 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.19, for a total value of $146,963.25.
• On Thursday, May 16th, Natarajan Sethuraman sold 1,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $15,000.00.

Entrada Therapeutics Trading Down 1.4 %

Shares of Entrada Therapeutics stock opened at $16.88 on Friday. The business’s 50 day simple moving average is $15.34 and its 200-day simple moving average is $14.37. The stock has a market capitalization of $569.87 million, a price-to-earnings ratio of 26.79 and a beta of -0.25. Entrada Therapeutics, Inc. has a twelve month low of $10.75 and a twelve month high of $18.17.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $1.06. The business had revenue of $59.12 million for the quarter, compared to analysts’ expectations of $25.00 million. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%. Sell-side analysts predict that Entrada Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Institutional Trading of Entrada Therapeutics

Several large investors have recently added to or reduced their stakes in the business. New York State Teachers Retirement System bought a new position in Entrada Therapeutics during the 1st quarter valued at $27,000. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics in the first quarter valued at $79,000. Tower Research Capital LLC TRC lifted its holdings in shares of Entrada Therapeutics by 476.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company’s stock valued at $87,000 after purchasing an additional 4,777 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Entrada Therapeutics by 27.7% during the fourth quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock worth $177,000 after acquiring an additional 2,540 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Entrada Therapeutics by 427.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their price objective on Entrada Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, June 25th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.